Related Experiment Videos
Biopharmaceuticals in Allergic Disease: Finding the Right Patients at the Right Time
1ASTHMA Inc. Clinical Research Center, Northwest Asthma and Allergy Center, University of Washington, 9725 Third Avenue NE, Suite 500, Seattle, WA 98115, USA.
Immunology and Allergy Clinics of North America
|April 4, 2017
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Pragmatic Strategies for Reducing Variability and Risk in Food Oral Immunotherapy.
Clinical reviews in allergy & immunology·2026
IgE and IgG4 epitopes of the peanut allergens shift following oral immunotherapy.
Frontiers in allergy·2023
Manufacturing processes of peanut (Arachis hypogaea) allergen powder-dnfp.
Frontiers in allergy·2022
Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2022
Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice.
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2022
Atopic Dermatitis: The Role of the Social Determinants of Health on Severity and Access to Care.
Immunology and allergy clinics of North America·2026
Exploring the Association Between Atopic Dermatitis and Malignancy: A Comprehensive Review with Therapeutic Strategies.
Immunology and allergy clinics of North America·2026
Management of Atopic Hand Dermatitis.
Immunology and allergy clinics of North America·2026
Special Considerations in Atopic Dermatitis in Young Children.
Immunology and allergy clinics of North America·2026
Contact Allergy Screening for Atopic Dermatitis.
Immunology and allergy clinics of North America·2026
Timing of Food Introduction and Allergy Prevention: An Update.
Immunology and allergy clinics of North America·2026
Scopolamine ameliorates psoriasis by blocking M1 receptor-mediated IL-23 production in dendritic cells.
Journal of immunology (Baltimore, Md. : 1950)·2026
Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals.
Handbook of experimental pharmacology·2026
Must RAAS-modifying drugs be withdrawn for the diagnosis of primary aldosteronism?
The Journal of clinical endocrinology and metabolism·2026
Combination Treatment of IL-17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review.
Immunity, inflammation and disease·2026